MENU
Aligos Therapeutics (ALGS) Ownership - Who owns Aligos Therapeutics?
Profile
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
38.16M
P/E Ratio
N/A
Total Cash
94.54M
Projected Growth
N/A
Total Debt
9.84M
Revenue
7.97M
Risk (Beta)
2.08
Dividend Yield
N/A
Total Cash/Share
29.58
Total Debt/Equity
N/A
Revenue/Share
1.65 USD as % of share price
Fundamentals
ALGS
Capitalization
38.2M
P/E Ratio
N/A
Risk (Beta)
2.08
Dividend Yield
N/A
Total Cash
94.5M
Total Cash/Share
29.58
Total Debt
9.84M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
1.65%
Revenue
7.97M
ROE
N/A
Book Value
67.2M
P/B Ratio
0.57
Cash Flow
N/A
Earnings
-14.5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
8K
Current Ratio
4.23
Current Revenue Per Employee
15602.94
Dividends Per Share - Security
N/A
EBITDA
-90.79M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-70.47
Shares Held By Institutions
21.5M
Shares Outstanding - Current
3.2M
Total Liabilities
41.6M
Total Volume MTD
N/A
Value
1
Gain YTD
-28.072
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
66
Web
https://www.aligos.com